Proactive Investors - Run By Investors For Investors

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors.

It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations with leading universities and pharmaceutical companies.

Dr Sandler says all is on track and work is “progressing successfully” towards  the goal of submitting an investigational new drug application to the US Food and Drug Administration for their CDX antibodies product.

 
View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use